Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317666 | 0.92 | ALDH1A1 (0.69) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15319394 | 0.87 | ALDH1A1 (0.62) | MAPTALDH1A1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL12412643 | 0.83 | MEN1 (0.62) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17886736 | 0.82 | L3MBTL3 (0.56) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL270344 | 0.81 | ALDH1A1 (0.71) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15317669 | 0.80 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15317801 | 0.80 | ALDH1A1 (0.52) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15317656 | 0.77 | MEN1 (0.66) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10195712 | 0.77 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL15317689 | 0.77 | MEN1 (0.66) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | MAPT 2022/4885ALDH1A1 875/4885SMN1; SMN2 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.